Table 1.
Clinical Characteristics of 52 patients.
| Clinical Characteristics | Total | Antiangiogenic group N (%) | Control Group N (%) | P Value |
|---|---|---|---|---|
| Patients | 52(100) | 22 (42.3) | 30 (57.7) | |
| Gender | 0.442 | |||
| Male | 44 (84.6) | 20 (90.1) | 24 (80) | |
| Female | 8 (15.4) | 2 (9.9) | 6 (20) | |
| Age | 0.399 | |||
| Median | 67 | 67 | 67.5 | |
| Range | 49-80 | 49-75 | 54-80 | |
| <65 | 20 (38.5) | 7 (31.8) | 13 (43.3) | |
| >65 | 32 (61.5) | 15 68.2) | 17 (56.7) | |
| Smoke | 0.640 | |||
| Yes | 36 (69.2) | 16 (72.2) | 20 (66.7) | |
| No | 16 (30.8) | 6 (27.3) | 10 (33.3) | |
| Stage | 0.575 | |||
| III | 19 (36.5) | 9 (40.9) | 10 (33.3) | |
| IV | 33 (63.5) | 13(59.1) | 20 (66.7) | |
| Pathologic Types | 0.473 | |||
| Adenocarcinoma | 29 (55.8) | 11(50) | 18 (60) | |
| Squamous Carcinoma | 23 (44.2) | 11(50) | 12 (40) | |
| Classification of ILD | 0.782 | |||
| IPF | 6 (11.5) | 2 (9.1) | 4 (13.3) | |
| Non-IPF | 46 (88.5) | 20 (90.9) | 26 (86.7) | |
| ILD pattern | 0.708 | |||
| UIP Type | 8 (15.4) | 4(18.2) | 4 (13.3) | |
| Non-UIP Type* | 44 (84.6) | 18(81.8) | 26 (86.7) | |
| Cycle | 0.190 | |||
| <4 | 17 (32.7) | 5(22.7) | 12 (40) | |
| ≥4 | 35 (67.3) | 17(77.3) | 18 (60) | |
| Regimens | 0.176 | |||
| AP | 24 (46.2) | 7 (31.8) | 17 (56.7) | |
| GP | 19 (36.5) | 9 (40.9) | 10 (33.3) | |
| TP | 4 (7.7) | 2 (9.1) | 2 (6.7) | |
| PEM | 5 (9.6) | 4 (18.2) | 1 (3.3) |
AP, pemetrexed+cisplatin; GP, gemcitabine+cisplatin; TP, nano albumin paclitaxel +platinum; PEM, pemetrexed.
*Non-IPF including nonspecific interstitial pneumonia (NSIP) (89%), desquamative interstitial pneumonitis (DIP) (4.5%) and respiratory bronchiolitis-associated interstitial lung disease (RB-ILD) (6.5%)